- Home
- ESAB vs ROIV Comparison
ESAB vs ROIV Comparison
Compare ESAB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESAB
- ROIV
- Stock Information
- Founded
- ESAB 1904
- ROIV 2014
- Country
- ESAB United States
- ROIV United Kingdom
- Employees
- ESAB N/A
- ROIV N/A
- Industry
- ESAB Office Equipment/Supplies/Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ESAB Industrials
- ROIV Health Care
- Exchange
- ESAB Nasdaq
- ROIV Nasdaq
- Market Cap
- ESAB 6.9B
- ROIV 8.4B
- IPO Year
- ESAB N/A
- ROIV N/A
- Fundamental
- Price
- ESAB $123.10
- ROIV $10.87
- Analyst Decision
- ESAB Buy
- ROIV Buy
- Analyst Count
- ESAB 8
- ROIV 4
- Target Price
- ESAB $136.50
- ROIV $17.50
- AVG Volume (30 Days)
- ESAB 266.4K
- ROIV 5.2M
- Earning Date
- ESAB 05-01-2025
- ROIV 05-29-2025
- Dividend Yield
- ESAB 0.32%
- ROIV N/A
- EPS Growth
- ESAB 16.34
- ROIV N/A
- EPS
- ESAB 4.43
- ROIV N/A
- Revenue
- ESAB $2,729,197,000.00
- ROIV $122,585,000.00
- Revenue This Year
- ESAB N/A
- ROIV N/A
- Revenue Next Year
- ESAB $4.79
- ROIV N/A
- P/E Ratio
- ESAB $27.94
- ROIV N/A
- Revenue Growth
- ESAB N/A
- ROIV 140.04
- 52 Week Low
- ESAB $88.54
- ROIV $8.73
- 52 Week High
- ESAB $135.97
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- ESAB 48.77
- ROIV 51.00
- Support Level
- ESAB $127.61
- ROIV $10.58
- Resistance Level
- ESAB $130.06
- ROIV $11.07
- Average True Range (ATR)
- ESAB 2.69
- ROIV 0.30
- MACD
- ESAB -0.49
- ROIV -0.04
- Stochastic Oscillator
- ESAB 21.16
- ROIV 30.21
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.